CF Industries Holdings, Inc. vs GSK plc — how do they compare? CF Industries Holdings, Inc. trades at $117.34 (market cap $17.83B), while GSK plc trades at $50.61 (market cap $102.60B). The key difference: GSK plc is far larger — about 5.8× CF Industries Holdings, Inc.'s market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| CF | GSK | |
|---|---|---|
Market Cap | $17.83B | $102.60B |
Sector | Basic Materials | Health |
52-Week High | $137.55 | $61.18 |
52-Week Low | $76.08 | $38.22 |
Enterprise Value | $18.96B | $123.04B |
Dividend Yield | 2.04% | 3.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →